Research and Markets: Forecast Insight: Top 20 Cancer Therapy Brands - Targeted Therapies Will Drive Market Growth in the Wake of the Cytotoxic and Antihormonal Patent Cliff

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/9368ec/forecast_insight) has
announced the addition of the "Forecast Insight: Top 20 Cancer Therapy Brands"
report to their offering.

Targeted therapies will drive market growth in the wake of the cytotoxic and
antihormonal patent cliff

The cancer therapies market offers a high level of commercial reward to a
handful of companies including Roche, Sanofi-Aventis, AstraZeneca, Novartis and
Eli Lilly. Cancer therapy sales totaled over $38 billion in the seven major
pharmaceutical markets in 2008, growing at a CAGR of 17.4% between 2005 and
2008.

Scope:

* Forecast sales of the leading 20 cancer therapy brands in each of the seven
major markets over the period 2008 to 2018
* Analysis and segmentation of the total cancer therapies market at various
levels including drug class, country and brand
* Comprehensive profiles and analysis for the key brands, including approval
dates, patent expiries and all key events likely to impact sales
* Snapshot of the cancer therapies market in the rest of the world

Highlights:

* The cancer therapies market is forecast to reach sales of $70.4 billion by
2018. Sales growth over the forecast period will slow as some of the highest
selling brands undergo patent expiry and several other brands will approach
market saturation.
* Molecular targeted therapies will continue to drive most of the growth of the
cancer therapies market over the forecast period 20082018. This reflects this
class's potential for increased uptake in existing indications, further
indication expansions, relatively low incursion from generics and the modest
impact of biosimilar market entrants.
* Roches monoclonal antibody franchise dominated the cancer therapies market in
2008 and will continue to do so through to 2018. Avastin was the top selling
cancer therapy brand in 2008 and will remain the leading brand through to 2018.
Expansion across a number of new tumor types and increasing uptake in new
territories will drive this growth.

Reasons to Purchase:

* Quantify the performance of each of leading 20 cancer therapies in the seven
major markets over the period 2008 to 2018
* Assess the changing key opportunities and threats both for currently marketed
and pipeline cancer therapy brands
* Identify the leading brands in this market over the next 10 years and
understand the key factors driving their success

For more information visit
http://www.researchandmarkets.com/research/9368ec/forecast_insight

Source: Datamonitor

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2009